image

Report Scope & Overview:

Glioblastoma Multiforme Treatment Market size was valued at USD 2.64 billion in 2022 and is expected to reach at USD 5.07 billion by 2030 and grow at a CAGR of 8.5% over the forecast period of 2023-2030.

The medications, medical equipment, and treatments utilised in the management of GBM are all included in the glioblastoma multiforme treatment market. The rise in brain cancer cases, the demand for higher survival rates, and continued efforts in research and development to find novel treatment modalities all contribute to the market's growth with regard to the initial care of GBM, surgery is essential. The goal of surgery is to remove as much of the tumour as feasible without harming important parts of the brain. However, due to the infiltrative nature of GBM cells, total resection is frequently not possible. Radiation therapy is frequently used as a follow-up following surgery to target any tumour cells that may still be present and lower the likelihood of recurrence. Chemotherapy is a crucial part of the treatment for GBM. Temozolomide (TMZ), the standard chemotherapy medication, is frequently given along with radiation therapy and subsequently maintained as maintenance therapy. However, TMZ can cause GBM tumours to become resistant, which reduces its effectiveness. Therefore, the creation of innovative chemotherapeutic drugs is required to combat resistance and enhance therapeutic results.

Glioblastoma Multiforme Treatment Market Revenue Analysis

The development of targeted therapeutics and immunotherapies has been facilitated by major improvements in our understanding of the biology of GBM in recent years. Inhibiting certain biological pathways or mutations that fuel tumour development is the goal of targeted therapy. For instance, erlotinib and gefitinib, which are EGFR inhibitors, have being researched as potential treatments for GBM. Personalised vaccinations and checkpoint inhibitors are examples of immunotherapies are being investigated in order to activate the patient's immune system to identify and eliminate GBM cells.

IMPACT OF COVID-19

Delayed Diagnosis and Treatment due to the pandemic, ordinary healthcare services, such as screenings and diagnostic procedures, have been disrupted. Because of this, the diagnosis of GBM could have been missed, which would have delayed the start of therapy. Delays in diagnosis might affect patient outcomes and reduce available alternatives for therapy. Disruption of Clinical Trials the pandemic had an impact on a number of clinical trials looking at novel GBM treatment options. Due to limitations on patient recruitment and follow-up visits, enrollment in clinical studies may have been delayed down or stopped entirely. The advancement of science and the accessibility of potentially ground-breaking treatments have been slowed down by this disturbance. Limited Access to Healthcare Facilities due to movement restrictions and the management of COVID-19 patients, limited access to healthcare facilities has been experienced by GBM patients. Patients may not have received prompt treatment and follow-up care due to travel limitations and anxieties about visiting hospitals and clinics. Impact on Supply networks the epidemic has impacted the world's pharmaceutical and medical device supply networks. The accessibility of vital medications and medical equipment required to treat GBM may have been impacted by this disruption. Treatment plans and patient outcomes may have been affected by supply chain delays or shortages.

MARKET DYNAMICS

 DRIVERS

  • Technical developments in diagnosis and treatment, as well as rising research and development spending.
  • Growing Incidence a prominent market driver is a global increase in glioblastoma multiforme treatment market.

The market is significantly being driven by the increased prevalence of GBM worldwide. The rising prevalence is a result of the ageing population, environmental variables, and improved diagnostic tools. Modern diagnostic methods that enable early detection and individualized treatment strategies include sophisticated imaging technologies (MRI, PET scans), molecular profiling, and genetic sequencing. To find novel medications, targeted therapies, and combination therapy for GBM, pharmaceutical companies, biotechnology companies, and research institutes are investing in R&D.

RESTRAIN

  • There are two types of restrain are their bad prognosis and High cost of care.

Despite having therapies, GBM has a terrible prognosis and a low survival rate. The disease's difficult characteristics, such as its aggressiveness, quick development, and resistance to therapy, place a heavy burden on the market. Treatments for GBM can be quite expensive, including surgery, radiation therapy, and chemotherapy. Particularly in areas with a lack of insurance coverage or inadequate healthcare resources, this high cost may restrict access to therapies.

OPPORTUNITY

  • In this we had a lots of opportunities like Research in Collaboration, Latest Therapies, Individualized Medicine.

There are prospects for better treatment results and improved patient care as a result of the development of innovative medicines such immunotherapies, targeted therapies, and tumor-treating fields (TTFields). The development of molecular profiling and genomics opens the door to personalized treatment strategies for GBM. Individual tumor features can be used to tailor treatments, thereby enhancing patient outcomes and response rates. Collaboration between pharmaceutical firms, academic institutions, and regulatory bodies can encourage creativity and hasten the creation of novel GBM therapies.

CHALLENGES

  • It might take a long time and be difficult to meet regulatory standards for authorising novel medicines.

  • Standard therapies for GBM are frequently ineffective, which causes the cancer to return.

Strict regulatory guidelines may cause a delay in the accessibility of medicines for GBM sufferers. The management of GBM presents a considerable difficulty in overcoming treatment resistance, necessitating the creation of novel therapeutic approaches.

 Data on the overall survival of GBM patients are still scarce because of the aggressiveness of the disease and the difficulties in conducting lengthy clinical studies. The evaluation of therapy effectiveness and long-term results is hampered by the absence of comprehensive survival statistics.

IMPACT OF RUSSIAN UKRAINE-WAR

The ongoing war between Russia and Ukraine has broad ramifications that may have an effect on a number of industries, particularly the healthcare sector and the market for the treatment of glioblastoma multiforme (GBM). While it's crucial to keep in mind that the specific effect on the market for GBM treatments may be indirect or secondary. Supply Chain Disruption war may cause disruptions in the supply of medications, medical equipment, and other healthcare items. This interruption may cause delays or shortages in the delivery of GBM treatment medications, tools, or supportive care items, limiting patients' access to life-saving treatments. Healthcare Infrastructure Challenges in the afflicted areas, the war may harm the healthcare infrastructure, including hospitals, clinics, and research facilities. This harm may affect how GBM therapies are administered, how people may access specialised healthcare providers, and how clinical trials and research projects are carried out. Armed conflicts might result in economic instability, which could have indirect effects on the market for GBM treatments. Economic downturns have the potential to have an influence on the accessibility and cost of healthcare through affecting healthcare budgets, research funding, and reimbursement rules in GBM treatment.

IMPACT OF ONGOING RECESSION

Reduction in Healthcare Spending during a recession, governments, healthcare systems, and people may experience financial difficulties, which will result in a reduction in healthcare spending. As a result, there may be insufficient financing for GBM research, lower treatment reimbursement, and lessened access to specialised GBM healthcare facilities. Delayed or Deferred procedures people may postpone or refuse non-emergency medical procedures, like as GBM therapy, during economic downturns. Delay in diagnosis, illness progression, and perhaps worse patient outcomes are all possible effects of this. Research and development financing issues recessions can have a detrimental influence on funding for these projects. The development of novel GBM treatment options and cutting-edge medicines may be slowed by decreased investment and financial resources for pharmaceutical companies, biotechnology businesses, and academic institutions.

KEY MARKET SEGMENTATION

By Product:

  • Surgery

  • Radiation treatment

  • Chemotherapy

  • Targeted Treatment

  • Therapy using a tumor-treating field (TTF)

  By Drug:

  • Temozolomide

  • Bevacizumab

  • Other

By End users:

  • Hospitals

  • Clinics

  •  Ambulatory Surgery Facilities

Glioblastoma Multiforme Treatment Market Segmentation Analysis

REGIONAL COVERAGE:

North America

  • USA

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

Asia-Pacific

  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of the Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin American

Key Players:

The Key players are Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc. & Other Players.

Amgen, Inc-Company Financial Analysis

​​​​​​​

RECENT DEVELOPMENT:

Pfizer Inc:  By lowering the rates of infection, sickness, and mortality globally, a vaccine is an essential component in the battle against COVID-19. To make the Pfizer-BioNTech COVID-19 Vaccine available as soon and safely as possible, Pfizer and BioNTech made use of decades of scientific knowledge to develop and carry out a rigorous Phase 3 clinical trial programme.

Glioblastoma Multiforme Treatment Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 2.64 Bn
Market Size by 2030  US$ 5.07 Bn
CAGR   CAGR of 8.5% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product Type (Surgery, Radiation treatment, Chemotherapy, Targeted Treatment, Therapy using a tumour-treating field (TTF))
• By Drug (Temozolomide, Bevacizumab, Other)
• By End users (Hospitals, Clinics, Ambulatory Surgery Facilities)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc.
Key Drivers • Technical developments in diagnosis and treatment, as well as rising research and development spending.
• Growing Incidence a prominent market driver is a global increase in glioblastoma multiforme treatment market.
Market Opportunities • In this we had a lots of opportunities like Research in Collaboration, Latest Therapies, Individualized Medicine.

 

Frequently Asked Questions

Ans The market size of glioblastoma multiforme was estimated to be worth USD 2.64 billion in 2022.

Ans: The CAGR growth rate of Glioblastoma Multiforme Treatment market is approx. CAGR of 8.5% predicted for the forecast period of 2023 to 2030.

Ans: There are some key players operating in the GBM treatment market include Merck & Co., Inc., Amgen, Inc., and F. Hoffmann-La Roche Ltd.

Ans: Glioblastoma multiforme is becoming more common, research and development spending is rising, the regulatory environment is favourable, and there is a robust pipeline of treatments for GBM.

Ans: In 2021, North America will have the largest share.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Global Glioblastoma Multiforme Treatment Market, By Product
8.1    Surgery
8.2    Radiation treatment
8.3    Chemotherapy
8.4    Targeted Treatment
8.5 Therapy using a tumor-treating field (TTF)

9. Global Glioblastoma Multiforme Treatment Market, By Drug
9.1    Temozolomide
9.2    Bevacizumab
9.10 Other

10. Global Glioblastoma Multiforme Treatment Market, By End users
10.1 Hospitals
10.2 Clinics
10.3 Ambulatory Surgery Facilities

11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Global Healthcare of Glioblastoma Multiforme Treatment Market by country
11.2.2North America Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.2.3 North America Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.2.4 North America Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.2.5 USA
11.2.5.1 USA Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.2.5.2 USA Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.2.5.3 USA Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.2.6 Canada
11.2.6.1 Canada Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.2.6.2 Canada Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.2.6.3 Canada Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.2.7 Mexico
11.2.7.1 Mexico Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.2.7.2 Mexico Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.2.7.3 Mexico Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.8 Europe
11.8.1 Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by country
11.8.2 Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.8.3 Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.8.4 Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.8.6 Germany
11.8.6.1 Germany Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.8.6.2 Germany Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.8.6.3 Germany Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.8.7 UK
11.8.7.1 UK Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.8.7.2 UK Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.8.7.3 UK Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.8.8 France
11.8.8.1 France Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.8.8.2 France Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.8.8.3 France Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.9.9 Italy
11.3.9.1 Italy Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.3.9.2 Italy Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.3.9.3 Italy Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.3.10 Spain
11.3.10.1 Spain Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.3.10.2 Spain Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.3.10.3 Spain Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.3.11 The Netherlands
11.3.11.1 Netherlands Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.3.11.2 Netherlands Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.3.11.3 Netherlands Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.3.12 Rest of Europe
11.3.11.1 Rest of Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.3.11.2 Rest of Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.3.11.3 Rest of Europe Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4 Asia-Pacific
11.4.1 Asia Pacific Global Healthcare of Glioblastoma Multiforme Treatment Market by country
11.4.2 Asia Pacific Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.3 Asia Pacific Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.4Asia Pacific Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.6 Japan
11.4.6.1 Japan Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.6.2 Japan Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.6.3 Japan Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.7 South Korea
11.4.7.1 South Korea Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.7.2 South Korea Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.7.3 South Korea Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.8 China
11.4.8.1 China Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.8.2 China Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.8.3 China Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.9 India
11.4.9.1 India Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.9.2 India Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.9.3 India Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.10 Australia
11.4.10.1 Australia Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.10.2 Australia Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.10.3 Australia Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.4.11 Rest of Asia-Pacific
11.4.11.1 APAC Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.4.11.2 APAC Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.4.11.3 APAC Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by country
11.5.2 The Middle East & Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.5.3 The Middle East & Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.5.4The Middle East & Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.5.6 Israel
11.5.6.1 Israel Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.5.6.2 Israel Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.5.6.3 Israel Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.5.7 UAE11.5.7.1 UAE Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.5.7.2 UAE Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.5.7.3 UAE Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.5.8 South Africa
11.5.8.1 South Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.5.8.2 South Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.5.8.3 South Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.5.9 Rest of Middle East & Africa
11.5.9.1 Rest of Middle East & Asia Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.5.9.2 Rest of Middle East & Asia Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.5.9.3 Rest of Middle East & Asia Global Healthcare of Sleep Disorder Treatment Market. End-User
11.6 Latin America
11.6.1 Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by country
11.6.2 Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.6.3 Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.6.4 Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.6.6 Brazil11.6.6.1 Brazil Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.6.6.2 Brazil Africa Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.6.6.3Brazil Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.6.7 Argentina
11.6.7.1 Argentina Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.6.7.2 Argentina Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.6.7.3 Argentina Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by Product Type
11.6.8.2 Rest of Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by drug
11.6.8.3 Rest of Latin America Global Healthcare of Glioblastoma Multiforme Treatment Market by End-User

12 Company profile
12.1 Merck & Co., Inc.
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Treatment/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Amgen, Inc.
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Treatment/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 F. Hoffmann-La Roche Ltd.
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Treatment/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Pfizer Inc
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Treatment/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Amgen, Inc.
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Treatment/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Teva Pharmaceutical Industries Ltd
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Treatment/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Sun Pharmaceutical Industries Ltd
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Treatment/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Arbor Pharmaceuticals
12.8.2 Financials
12.8.3 Treatment/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Amneal Pharmaceuticals
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Treatment/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10.  Karyopharm Therapeutics Inc.
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Treatment/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View

13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments

14. Use Cases and Best Practices

15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone